F
Fathi Elloumi
Researcher at General Dynamics
Publications - 5
Citations - 284
Fathi Elloumi is an academic researcher from General Dynamics. The author has contributed to research in topics: Cancer & Copy-number variation. The author has an hindex of 3, co-authored 5 publications receiving 124 citations. Previous affiliations of Fathi Elloumi include Government of the United States of America & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.
Vinodh N. Rajapakse,Augustin Luna,Mihoko Yamade,Lisa Loman,Sudhir Varma,Margot Sunshine,Francesco Iorio,Fabricio G. Sousa,Fathi Elloumi,Mirit I. Aladjem,Anish Thomas,Chris Sander,Kurt W. Kohn,Cyril H. Benes,Mathew J. Garnett,William C. Reinhold,Yves Pommier +16 more
TL;DR: The value of CellMinerCDB in selecting drugs with reproducible activity is demonstrated, the dominant role of SLFN11 for drug response is expanded, and novel response determinants and genomic signatures for topoisomerase inhibitors and schweinfurthins are presented.
Journal ArticleDOI
CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics.
Augustin Luna,Fathi Elloumi,Sudhir Varma,Yang-Hsin Wang,Vinodh N. Rajapakse,Mirit I. Aladjem,Jacques Robert,Chris Sander,Yves Pommier,William C. Reinhold +9 more
TL;DR: The curation and common annotations provided here across pharmacogenomic datasets increase the utility of the individual datasets to address multiple researcher question types, including data reproducibility, biomarker discovery and multivariate analysis of drug activity.
Journal ArticleDOI
RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB
William C. Reinhold,Sudhir Varma,Sudhir Varma,Margot Sunshine,Margot Sunshine,Fathi Elloumi,Fathi Elloumi,Kwabena Ofori-Atta,Sunmin Lee,Jane B. Trepel,Paul S. Meltzer,James H. Doroshow,Yves Pommier +12 more
TL;DR: This work introduces RNA sequencing data for the NCI-60 and their access and integration with the other databases, and reveals cell-specific differences in the overall levels of isoforms and shows their linkage to expression of RNA processing and splicing genes as well as resultant alterations in cancer and pharmacological gene sets.
Journal ArticleDOI
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents
Ukhyun Jo,Ilya S. Senatorov,Astrid Zimmermann,Liton Kumar Saha,Yasuhisa Murai,Se Hyun Kim,Vinodh N. Rajapakse,Fathi Elloumi,Nobuyuki Takahashi,Christopher W. Schultz,Anish Thomas,Frank Zenke,Yves Pommier +12 more
TL;DR: In this article, a new ATR-based chemotherapy drug, M4344, was proposed and compared with the clinically developed ATR inhibitors BAY1895344, berzosertib, and ceralasertib using in vitro and in vivo models.